fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Qsymia side effects: Cognitive disorders (problems with concentration, memory) in 7.6% of patients


    Posted by .(JavaScript must be enabled to view this email address)
    Friday, July 20, 2012 12:35 pm Email this article

    Cognitive disorders (problems with attention / concentration, memory, and language (word finding)) occurred in 7.6% of subjects given the higher dose of Qsymia (15 mg phentermine / 92 mg topiramate) versus 1.5% of people given a placebo according to the prescribing information for the drug.

    Cognitive Disorders

    Cognitive Disorders : Problems with attention / concentration, memory, and language (word finding).

    “In the 1-year controlled trials of Qsymia, the proportion of patients who experienced one or more cognitive- related adverse reactions was 2.1% for Qsymia 3.75 mg/23 mg, 5.0% for Qsymia 7.5 mg/46 mg, and 7.6% for Qsymia 15 mg/92 mg, compared to 1.5% for placebo,” notes the prescribing information.

    “These adverse reactions were comprised primarily of reports of problems with attention/concentration, memory, and language (word finding).

    “These events typically began within the first 4 weeks of treatment, had a median duration of approximately 28 days or less, and were reversible upon discontinuation of treatment; however, individual patients did experience events later in treatment, and events of longer duration.”

    Info about Qseymia

    Info about Qseymia from the FDA

    The following information is from the FDA’s press release.

    “The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

    “BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories.

    “According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

    “Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

    “Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

    “Qsymia is a combination of two FDA-approved drugs, phentermine and topiramate, in an extended-release formulation.

    “Phentermine is indicated for short-term weight loss in overweight or obese adults who are exercising and eating a reduced calorie diet.

    “Topiramate is indicated to treat certain types of seizures in people who have epilepsy and to prevent migraine headaches.”

    Reference

    Qsymia full prescribing information. July 17, 2012.
    http://www.qsymia.com/pdf/full-prescribing-information.pdf

    More Info

    More info about Qsymia here

    Drug companies website:

    Other Articles

    Other articles about Qsymia (formerly Qnexa)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.